Pazopanib
- Generic Name
- Pazopanib
- Brand Names
- Votrient
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N7O2S
- CAS Number
- 444731-52-6
- Unique Ingredient Identifier
- 7RN5DR86CK
- Background
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
- Indication
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
- Associated Therapies
- -
Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma
- First Posted Date
- 2006-07-11
- Last Posted Date
- 2013-04-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 75
- Registration Number
- NCT00350727
Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
- First Posted Date
- 2006-06-07
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 435
- Registration Number
- NCT00334282
- Locations
- 🇬🇧
GSK Investigational Site, Swansea, United Kingdom
Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-02-28
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 148
- Registration Number
- NCT00297258
- Locations
- 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath